MarkChandrahantLakshmananMD

PubMed

• 2 citations
  Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.
  Tali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, M Angelyn Bethel, Ernesto G Cardona-Muñoz, Ignacio Conget, Gilles Dagenais, Edward Franek, Stephanie Hall, Nicola...> ;The Journal of Clinical Endocrinology and Metabolism. 2022 Jul 14
• 23 citations
  Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
  Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles Atisso, Mark Lakshmanan, Reema Mody, Sohini Raha, Hertzel C. Gerstein> ;Cardiovascular Diabetology. 2021 Sep 25
• 16 citations
  Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline...
  Giulia Ferrannini, Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Diaz, Leanne Dyal, Mark Lakshmanan, Linda Mellbin, Jeffrey L. Probstfield, Matthew...> ;European Heart Journal. 2021 Jul 8
• 15 citations
  Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
  Harpreet S. Bajaj, Hertzel C. Gerstein, Purnima Rao-Melacini, Jan Basile, Helen M. Colhoun, Ignacio Conget, William C. Cushman, Gilles R. Dagenais, Edward Franek, Mark...> ;The Lancet. Diabetes & Endocrinology. 2021 Aug 1
• 12 citations
  Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
  Matthew C. Riddle, Hertzel C. Gerstein, Denis Xavier, William C. Cushman, Lawrence A. Leiter, Peter J Raubenheimer, Charles Atisso, Sohini Raha, Oralee J. Varnado, Man...> ;The Journal of Clinical Endocrinology and Metabolism. 2021 Apr 23
• 38 citations
  HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.
  M. Angelyn Bethel, Rafael Diaz, Noelia Castellana, Indranil Bhattacharya, Hertzel C. Gerstein, Mark Lakshmanan> ;Diabetes Care. 2021 Jan 1
• 11 citations
  Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
  Gilles R. Dagenais, Lars Rydén, Lawrence A. Leiter, Mark Lakshmanan, Leanne Dyal, Jeffrey L. Probstfield, Charles Atisso, Jonathan E. Shaw, Ignacio Conget, William C. ...> ;Cardiovascular Diabetology. 2020 Nov 25
• 96 citations
  Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
  Tali Cukierman-Yaffe, Hertzel C. Gerstein, Helen M. Colhoun, Rafael Diaz, Luis-Emilio Garcia-Perez, Mark Lakshmanan, Angelyn Bethel, Denis Xavier, Jeffrey L. Probstfie...> ;The Lancet. Neurology. 2020 Jul 1
• 64 citations
  The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
  Hertzel C. Gerstein, Robert G. Hart, Helen M. Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T. Botros, Jeffrey L. Probstfield, Matthew C. Riddle, Lars Rydén, Charles Ati...> ;The Lancet. Diabetes & Endocrinology. 2020 Jan 7
• 32 citations
  Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
  Kristina S. Boye, Matthew C. Riddle, Hertzel C. Gerstein, Reema Mody, Luis-Emilio Garcia-Perez, Chrisanthi A. Karanikas, Maureen J. Lage, Jeffrey S. Riesmeyer, Mark La...> ;Diabetes, Obesity & Metabolism. 2019 Jun 1
• 18 citations
  Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)
  Katherine R. Tuttle, Mark Lakshmanan, Brian Rayner, Alan G. Zimmermann, D. Bradley Woodward, Fady T. Botros> ;Diabetes, Obesity & Metabolism. 2019 Jun 1
• GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply.
  Katherine R. Tuttle, Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann, D. Bradley Woodward, Fady T. Botros> ;The Lancet. Diabetes & Endocrinology. 2018 Oct 1
• 342 citations
  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
  Katherine R. Tuttle, Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann, D. Bradley Woodward, Fady T. Botros> ;The Lancet. Diabetes & Endocrinology. 2018 Aug 1
• 5 citations
  No calcitonin change in a person taking dulaglutide diagnosed with pre‐existing medullary thyroid cancer
  Steven I. Sherman, Richard T. Kloos, R. M. Tuttle, A. Pontecorvi, Henry Völzke, K. Harper, C. Vance, J. T. Alston, A. L. Usborne, K. W. Sloop, M. Lakshmanan> ;Diabetic Medicine. 2018 Mar 1
• 134 citations
  Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular ef...
  Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey L. Probstfield, Matthew C. Riddle, Lars Rydén, Denis Xavier...> ;Diabetes, Obesity & Metabolism. 2018 Jan 1
• 25 citations
  Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.
  Matthew Reaney, Maria Yu, Mark Lakshmanan, V. Pechtner, K van Brunt> ;Diabetes, Obesity & Metabolism. 2015 Sep 1
• 30 citations
  Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabe...
  Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan> ;Diabetes Care. 2014 Oct 1
• 245 citations
  Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
  Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan> ;Diabetes Care. 2014 Aug 1
• 85 citations
  The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
  Peyman Hadji, J.R. Zanchetta, L.A. Russo, Christopher Recknor, Kenneth G. Saag, Fergus McKiernan, Stuart L. Silverman, Jahangir Alam, Russel Burge, John H. Krege, Mark...> ;Osteoporosis International. 2012 Aug 1
• 374 citations
  Teriparatide for Acceleration of Fracture Repair in Humans: A Prospective, Randomized, Double-Blind Study of 102 Postmenopausal Women With Distal Radial Fractures
  Per Aspenberg, Harry K. Genant, Torsten Johansson, Antonio J. Nino, Kyoungah See, Kelly Krohn, Pedro A García-Hernández, Christopher P Recknor, Thomas A. Einhorn, Gail...> ;Journal of Bone and Mineral Research. 2010 Feb 1
• 23 citations
  Effects of Arzoxifene on Bone Mineral Density and Endometrium in Postmenopausal Women with Normal or Low Bone Mass
  Michael A. Bolognese, John H. Krege, W. H. Utian, R. Feldman, S. Broy, D. L. Meats, Jahangir Alam, Mark Lakshmanan, M. Omizo> ;The Journal of Clinical Endocrinology and Metabolism. 2009 Jul 1
• 15 citations
  Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy.
  Molly C. Carr, Robert H. Knopp, John D. Brunzell, Barbara S. Wheeler, Xiaodong Zhu, Mark Lakshmanan, Amy S. Rosen, Pamela W. Anderson> ;Diabetes Care. 2005 Jul 1
• 29 citations
  Carnitine Is a Naturally Occurring Inhibitor of Thyroid Hormone Nuclear Uptake
  Salvatore Benvenga, Mark Lakshmanan, Francesco Trimarchi> ;Thyroid. 2000 Dec 1
• 10 citations
  The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice.
  Ilene R. Cohen, Millie L Sims, Michelle R. Robbins, Mark Lakshmanan, Paul C Francis, Gerald G. Long> ;Reproductive Toxicology. 2000 Jan 1
• 57 citations
  Healthcare use among U.S. women aged 45 and older: total costs and costs for selected postmenopausal health risks.
  Thomas J. Hoerger, Kristen E. Downs, Mark Lakshmanan, Richard C. Lindrooth, Leo Plouffe, Brett Wendling, Suzanne L. West, Robert L. Ohsfeldt> ;Journal of Women's Health & Gender-Based Medicine. 1999 Oct 1
• Join now to see all